BioNTech Acquires Pumeast Biotechnology for 800 Million
| SPRC Stock | USD 0.35 0.01 2.94% |
About 54% of Scisparc's shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Scisparc suggests that some traders are interested. The current market sentiment, together with Scisparc's historical and current headlines, can help investors time the market. In addition, many technical investors use Scisparc stock news signals to limit their universe of possible portfolio assets.
BioNTech SE has announced an agreement to acquire 100 percent of the issued share capital of Pumeast Biotechnology Company for 800 million. The transaction will prima
Read at gurufocus.com
 |
Scisparc Fundamental Analysis
We analyze Scisparc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scisparc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scisparc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Scisparc is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Scisparc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scisparc stock to make a market-neutral strategy. Peer analysis of Scisparc could also be used in its relative valuation, which is a method of valuing Scisparc by comparing valuation metrics with similar companies.
Peers
Scisparc Related Equities
| CTMX | CytomX Therapeutics | 129.03 | ||||
| UNCY | Unicycive Therapeutics | 3.64 | ||||
| TIL | Instil Bio | 3.40 | ||||
| NUVB | Nuvation Bio | 2.87 | ||||
| REVB | Revelation Biosciences | 2.52 | ||||
| ZVSA | ZyVersa Therapeutics | 1.89 | ||||
| ASMB | Assembly Biosciences | 0.90 | ||||
| VRAX | Virax Biolabs | 0.94 | ||||
| QNRX | Quoin Pharmaceuticals | 1.13 | ||||
| KPRX | Kiora Pharmaceuticals | 1.85 | ||||
| HOTH | Hoth Therapeutics | 2.11 | ||||
| CVKD | Cadrenal Therapeutics, | 6.77 | ||||
| CDIO | Cardio Diagnostics | 15.79 |
Complementary Tools for Scisparc Stock analysis
When running Scisparc's price analysis, check to measure Scisparc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scisparc is operating at the current time. Most of Scisparc's value examination focuses on studying past and present price action to predict the probability of Scisparc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scisparc's price. Additionally, you may evaluate how the addition of Scisparc to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |